Long-Term Effects of Low-Dose Naltrexone on Immunomodulatory Properties of Human Adipose-Derived Mesenchymal Stem Cells

Long-Term Effects of Low-Dose Naltrexone on Immunomodulatory Properties of Human Adipose-Derived Mesenchymal Stem Cells

Background: Low-dose naltrexone (LDN) is involved in the treatment of inflammatory and immune system diseases and can affect immune cells. Mesenchymal stem cells (MSCs) are known for their immunomodulatory effects and the potential for the treatment of certain types of autoimmune diseases.Objective:...

Full description

Bibliographic Details
Main Authors:	Romina Kazemi, Mobin Mohammadi, Samira Salimiyan, Sara Aliakbari, Moslem Ahmadi, Mohammad Rahmani
Format:	Article
Language:	English
Published:	Shiraz University of Medical Sciences 2023-06-01
Series:	Iranian Journal of Immunology
Subjects:	adipose-derived mesenchymal stem cells immunomodulation inflammatory response ldn naltrexone
Online Access:	https://iji.sums.ac.ir/article_49268_ffb3b9ae4a4c279d2659d0ea673a8326.pdf

Similar Items

Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial
by: Karin Due Bruun, et al.
Published: (2021-11-01)

Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia
by: Luke Parkitny, et al.
Published: (2017-04-01)

Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis
by: Monica Bolton, et al.
Published: (2019-01-01)

Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy
by: Marianna Ciwun, et al.
Published: (2024-03-01)

Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization
by: Karlo Toljan, et al.
Published: (2018-09-01)

The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review
by: Yang J, et al.
Published: (2023-03-01)

Prospective of low dose naltrexone use in treatment of autoimmune pathology and endometriosis
by: O. V. Golianovskyi, et al.
Published: (2020-11-01)

Comparing the immunomodulatory properties of bone marrow, adipose tissue and birth-associated tissue mesenchymal stromal cells
by: Philipp eMattar, et al.
Published: (2015-11-01)

Precipitated withdrawal with kratom use following naltrexone administration
by: Jarka Courtney PharmD, BCPS, BCPP, et al.
Published: (2023-06-01)

Immunomodulatory effect of mesenchymal stem cells
by: Luciana Cavalheiro Marti, et al.
Published: (2011-06-01)

Treatment of repeated self- injurious behaviour with naltrexone: a case report
by: Praveen Navkhare, et al.
Published: (2013-12-01)

Thyroid Function of Former Opioid Addicts on Naltrexone Treatment
by: Ioannis Ilias, et al.
Published: (2001-01-01)

The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled clinical trial
by: Vahideh Lajevardi, et al.
Published: (2022-02-01)

Efficacy of Low-Dose Naltrexone and Predictors of Treatment Success or Discontinuation in Fibromyalgia and Other Chronic Pain Conditions: A Fourteen-Year, Enterprise-Wide Retrospective Analysis
by: C. Noelle Driver, et al.
Published: (2023-04-01)

Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats
by: Monica Alhadas Scudeler, et al.
Published: (2022-05-01)

Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases
by: Praneet Dara, et al.
Published: (2023-06-01)

Intranasal Low-Dose Naltrexone Against Opioid Side Effects: A Preclinical Study
by: Laura Micheli, et al.
Published: (2020-09-01)

Evaluation of Different Doses of Fentanyl in Controlling Agitation in Acute Opioid Withdrawal Syndrome Induced by Naltrexone Misuse
by: Farzad Gheshlaghi, et al.
Published: (2012-03-01)

Dominant Dystrophic Epidermolysis Bullosa Pruriginosa Responding to Naltrexone Treatment
by: Kristine A.U. Pallesen, et al.
Published: (2019-09-01)

No change in the consumption of thyroid hormones after starting low dose naltrexone (LDN): a quasi-experimental before-after study
by: Guttorm Raknes, et al.
Published: (2020-10-01)

Low Dose Naltrexone - Efficacy and safety of off-label use therapy.
by: Andrzej Stańczak
Published: (2020-01-01)

Low dose Naltrexone for induction of remission in inflammatory bowel disease patients
by: Mitchell R. K. L. Lie, et al.
Published: (2018-03-01)

Naltrexone Implant for Opioid Use Disorder
by: Amber N. Edinoff, et al.
Published: (2021-12-01)

Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series
by: McKenzie-Brown AM, et al.
Published: (2023-06-01)

The Study of the Demographic and Clinical and Laboratory Findings in Naltrexone Poisoning Patients Admitted to Razi Hospital, Rasht, During 2007-08
by: Morteza Rahbar Taromsar, et al.
Published: (2012-08-01)

Thermosensitive Gels Used to Improve Microneedle-Assisted Transdermal Delivery of Naltrexone
by: Kevin V. Tobin, et al.
Published: (2021-03-01)

Enhancement of Cisplatin Nephrotoxicity by Morphine and Its Attenuation by the Opioid Antagonist Naltrexone
by: Atefeh Aminian, et al.
Published: (2016-07-01)

Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives
by: Tek C
Published: (2016-05-01)

Immunomodulatory Effect of Human Umbilical Cord Blood-derived Mesenchymal Stem Cells on Activated T-lymphocyte
by: Parisa Lotfinejad, et al.
Published: (2021-12-01)

Naltrexone-induced acute generalized exanthematous pustulosis
by: Jason Eakes, BS, et al.
Published: (2023-09-01)

The effects of Naltrexone among alcohol non-abstainers: results from the COMBINE Study
by: Lara Ray, et al.
Published: (2010-10-01)

Comparing Naltrexone and Metformin Pretreatment for Inducing Ovulation in Patients With Polycystic Ovary Syndrome in Intrauterine Insemination Cycles
by: Afsun Zarei, et al.
Published: (2022-07-01)

The Effects of Low Dose Naltrexone on Opioid Induced Hyperalgesia and Fibromyalgia
by: Daniel Jackson, et al.
Published: (2021-02-01)

Immunometabolic Modulatory Role of Naltrexone in BV-2 Microglia Cells
by: Natalia Kučić, et al.
Published: (2021-08-01)

Association of low-dose naltrexone and transcranial direct current stimulation in fibromyalgia: a randomized, double-blinded, parallel clinical trial
by: Tânia Maria Hendges de Paula, et al.
Published: (2023-07-01)

Enhancing Immunomodulatory Function of Mesenchymal Stromal Cells by Hydrogel Encapsulation
by: Hui-Yun Cheng, et al.
Published: (2024-01-01)

Exploring genetic predictors of naltrexone treatment response in opioid use disorder
by: Е. A. Blokhina ., et al.
Published: (2019-12-01)

Comparison of General Well-being of Patients Undergoing Methadone Maintenance Therapy (MMT) with Patients Under-going Naltrexone Therapy
by: Mehdi Sayyah, et al.
Published: (2013-02-01)

Telomerase governs immunomodulatory properties of mesenchymal stem cells by regulating FAS ligand expression
by: Chider Chen, et al.
Published: (2014-03-01)

Intralymphatic Administration of Adipose Mesenchymal Stem Cells Reduces the Severity of Collagen-Induced Experimental Arthritis
by: Eleuterio Lombardo, et al.
Published: (2017-04-01)